Precision Test For Breast Cancer Treatment Remains Imprecise : Shots : npr

as declared in npr

Precision Test For Breast Cancer Treatment Remains Imprecise : Shots

Precision Test For Breast Cancer Treatment Remains Imprecise : Shots

Study Of Breast Cancer Treatment Reveals Paradox Of Precision MedicineEnlarge this image toggle caption Voisin/Phanie/Science Source Voisin/Phanie/Science SourceA major study about the best way to treat early-stage breast cancer reveals that "precision medicine" doesn't provide unambiguous answers about how to choose the best therapy."Precision doesn't mean certainty," says David Hunter, a professor of cancer prevention at Harvard's T.H.Chan School of Public Health.That point is illustrated in a large study published Wednesday in the New England Journal of Medicine, involving decisions about chemotherapy.


in like manner twcnews

Study Says Women with Early Stage Breast Cancer May Be Able to Skip Chemotherapy

Study Says Women with Early Stage Breast Cancer May Be Able to Skip Chemotherapy

CHARLOTTE -- For some women, surviving breast cancer may no longer need to involve chemotherapy.A new study published in the New England Journal of Medicine says based on a genetic make up of a tumor, if it shows that the risk of that cell growing or spread is low, women with early stage breast cancer could skip chemotherapy.But Dr. Ayla Kessler with Novant Health says it's important to remember the study looks at just one type of cancer, and every patient is different."But not to everybody of your stage of tumor or size of tumor, it just kind of hones in what your tumor is doing and what is best for you.," said Dr. Kessler.


by the same token on nejm

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer — NEJM

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer — NEJM

Background The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer.We sought to provide prospective evidence of the clinical utility of the addition of the 70-gene signature to standard clinical–pathological criteria in selecting patients for adjuvant chemotherapy.Methods In this randomized, phase 3 study, we enrolled 6693 women with early-stage breast cancer and determined their genomic risk (using the 70-gene signature) and their clinical risk (using a modified version of Adjuvant!Women at low clinical and genomic risk did not receive chemotherapy, whereas those at high clinical and genomic risk did receive such therapy.